Chiropractors in North St Paul, MN Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Dr. Matthew Gary Hyopponen, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2470 Mcknight Rd N, North St Paul, MN 55109 Phone: 651-777-3877 Fax: 651-773-0708 |
Sawyer A Hildebrant, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2516 7th Ave E, North St Paul, MN 55109 Phone: 651-770-3805 Fax: 651-747-8737 |
 Key Chiropractic, Ltd Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2597 7th Ave E, North St Paul, MN 55109 Phone: 651-770-8200 |
Austin Murdock, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2435 Seppala Blvd, North St Paul, MN 55109 Phone: 877-442-4476 |
News Archive
New research shows uremic toxins increase heart attack risk
MD-Patients with advanced kidney disease who are undergoing hemodialysis are known to be highly susceptible to heart attacks and other cardiovascular complications, and now scientists likely know why.
Accelerated partial breast irradiation therapy increases risk for subsequent mastectomy
Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy growing increasingly popular as a treatment choice for women with early-stage breast cancer, is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole breast irradiation (WBI), according to researchers from The University of Texas MD Anderson Cancer Center.
Hepatitis C therapy peginterferon alfa-2b shows promise
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).
BioAlliance Pharma's new drug application for oropharyngeal candidiasis treatment accepted by the FDA
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
OMA praises health care workers for their hard work and dedication during flu season
At its annual fall meeting, the Ontario Medical Association (OMA) recognized front line health care workers for their hard work and dedication to patient during this unprecedented flu season. The OMA Council, which represents doctors from across the province, overwhelmingly passed a motion to express its thanks to Medical Officers of Health, physicians, nurses, and other health care professionals for their leadership.
› Verified 1 days ago